Rahul Kakkar
CORPORATE STRATEGY
Corvidia Therapeutics
Switzerland
Biography
He is a founder and leads the clinical and strategic development activities at Corvidia. Rahul was Director for Emerging Innovations at AstraZeneca, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and compounds to support out-licensing efforts enabling the raise of over $85M in venture-backed capital. He is a founder of multiple biotechnology and digital medicine startup companies. Rahul dual-trained via the American Board of Internal Medicine Fast Track program in molecular biology and clinical cardiology. His research at the Brigham and Women’s and Massachusetts General Hospitals as well as TIMI Group in Boston focused on immune signaling and novel biomarkers in progressive heart failure. Rahul was a junior inductee of the Alpha Omega Alpha honor society and continues to practice critical-care medicine in Boston. Rahul received his BA/MD from Tufts University
Research Interest
preclinical trials
